MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
MaxCyte Inc MXCT
$1.17
▼ -1.68%
($-0.02)
Open
$1.20
Prev Close
$1.19
Day Range
$1.16 – $1.20
52W Range
$0.64 – $1.87
Market Cap
$120.75M
Beta
1.55
EPS (TTM)
$-0.33
📋 Company Profile
| Industry | Life Sciences Tools & Services |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-03-29 |
| Shares Out. | 107,120,000 |
| Website | maxcyte.com/ ↗ |
| Phone | 13015175556 |
| Employees | 91 |
| Revenue | $7.3M |
| Gross Profit | $5.6M |
| Net Income | -$8.9M |
| Free Cash Flow | -$23.6M |
| Total Assets | $184.7M |
| Total Liabilities | $25.9M |
| Equity | $158.8M |
About MaxCyte Inc
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
MaxCyte Inc is a publicly traded company under the ticker symbol MXCT on the NASDAQ NMS - GLOBAL MARKET, operating in the Life Sciences Tools & Services industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-09-01)